Daewoong Pharmaceutical, Joint Primate Research Collaboration with Local Indonesian Institution

Daewoong Pharmaceutical is embarking on a joint research project with the Bogor Agricultural University (IPB) in Indonesia to enhance competitiveness in the preclinical stage through primate research.

Park Sung-soo, CEO of Daewoong Pharmaceutical (left), and Iskandar, Vice Chancellor of IPB, are posing for a commemorative photo at the MOU signing ceremony for primate research cooperation.
[Photo by Daewoong Pharmaceutical]

On the 27th, Daewoong Pharmaceutical announced that it had signed a Memorandum of Understanding (MOU) with IPB for joint research collaboration related to primate studies. Through this partnership, both institutions plan to ▲establish a primate research institute at IPB ▲commercialize pharmaceuticals and medical devices through primate research ▲support the development of outstanding veterinary talent.

The establishment of the primate research institute holds significance in increasing the reliability of preclinical results by conducting studies on primates that naturally exhibit diseases similar to humans. This is explained as securing competitiveness in the preclinical stage, where toxicity and efficacy of new drug candidates are evaluated before administration to humans.

This collaboration will be carried out in cooperation with PSSP, an institution under IPB that has conducted primate research for over 30 years. PSSP is a research institution specializing in medicine, biology, and zoology, and obtained full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) in 2006. AAALAC is an international non-profit organization that sets and evaluates standards for animal research ethics and welfare. PSSP has actively conducted joint research with overseas researchers from countries such as the United States and Denmark, gaining diverse experience in primate research with major international institutions.

Iskandar, Vice President of IPB, stated, “IPB is the institution with the best primate research capabilities in Indonesia through international research cooperation,” and added, “We expect to create greater value with Daewoong Pharmaceutical.” Park Sung-soo, CEO of Daewoong Pharmaceutical, also said, "It is very meaningful to sign a business agreement with IPB, which represents Indonesia,” and “We will strive to strengthen our cooperative relationship in the future so that Daewoong Pharmaceutical’s new drug development and the growth of Indonesia’s pharmaceutical and bio industries can progress together.”